CytRx Corp other research news

CYTR has been informed that RheothRx is a candidate for testing in the fifth myocardial infarction trial by the ISIS study group. The International Study of Infarct Survival trials typically enroll 40,000 to 60,000 patients and have demonstrated the ability of several thrombolytic agents and beta blocker drugs to prevent death from heart attacks. ...